Sunitinib-induced hemoglobin changes are related to the dosing schedule.

Department of Medical Oncology, VU University Medical Center, Amsterdam, the Netherlands.
Journal of Clinical Oncology (Impact Factor: 18.04). 03/2009; 27(8):1339-40; author reply 1340-2. DOI: 10.1200/JCO.2008.20.6151
Source: PubMed
  • [Show abstract] [Hide abstract]
    ABSTRACT: We retrospectively analyzed hematologic parameters in 22 patients with advanced, nonsquamous, NSCLC undergoing VEGF inhibition on a phase II clinical trial of bevacizumab, carboplatin, and gemcitabine. We also examined TTP in relation to hemoglobin changes. Median hemoglobin increased significantly from a 12.9 g/dL pretreatment to 13.8 g/dL (p =.01) after the second cycle of maintenance bevacizumab until the first off cycle measurement. There was no difference in TTP in patients who achieved a rise in hemoglobin compared with patients who did not (median 238 days vs. 268 days, p =.38.) Maintenance bevacizumab is associated with increased hemoglobin in advanced, nonsquamous, NSCLC patients.
    Cancer Investigation 03/2012; 30(3):231-5. · 2.24 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The envelope constrained (EC) filtering problem is concerned with the design of a filter with minimum gain to white input noise and with a response to a given signal that fits into a prescribed envelope. Using the discrete-time orthonormal Laguerre network, the EC filtering problem is posed as a quadratic programming (QP) problem with affine inequality constraints. An iterative algorithm for solving this QP problem is proposed which serves as a basis for the derivation of adaptive algorithms for applications where the parameters of the underlying signal model are either not known or varying with time.
    Proceedings - ICASSP, IEEE International Conference on Acoustics, Speech and Signal Processing 01/1996; 3:1363-1366.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Inhibition of vascular endothelial growth factor (VEGF) signaling increases red blood cell (RBC) counts, and erythropoiesis markers have been proposed to guide antiangiogenic therapy in humans. We analyzed RBC measurements in patients enrolled in three studies: a phase II trial of axitinib in thyroid cancer; a study of sorafenib in advanced solid tumors; and a randomized trial of fluorouracil, hydroxyurea, and radiation with and without bevacizumab for head and neck cancer. In the sorafenib trial, plasma erythropoietin concentrations were measured at baseline, day 8, and day 35. Over the first 84 days of treatment, RBC counts increased for each day on sorafenib (2.7 M/μ L [95% confidence interval (CI), 1.5-3.9]) and axitinib (4.3 M/μ L [95% CI, 2.2-6.5]). RBCs declined over the first 68 days of cytotoxic chemoradiotherapy alone (-12.8 M/μ L per day [95% CI, -15.7 to -9.8]) but less so with added bevacizumab (-7.2 M/μ L per day [95% CI, -9.5 to -4.9]). Erythropoietin levels increased, on average, by 9.5 mIU/mL between day 8 and day 35 of sorafenib exposure. No significant relationships between elevations in RBCs and changes in volume status or blood pressure or between elevations in erythropoietin and smoking status were found. VEGF signaling inhibition is associated with increased RBC and erythropoietin production in humans. The effects of these changes are subtle at physiologic doses and are unlikely to be clinically useful biomarkers for guiding the administration of or predicting treatment responses to VEGF pathway inhibitors.
    The Oncologist 07/2013; · 4.10 Impact Factor


Available from